baquiloprim: used in veterinary medicine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9861430 |
| CHEMBL ID | 2105911 |
| SCHEMBL ID | 9007835 |
| MeSH ID | M0196934 |
| Synonym |
|---|
| baquiloprim |
| baquiloprime [french] |
| baquiloprima [spanish] |
| 5-((2,4-diamino-5-pyrimidinyl)methyl)-8-(dimethylamino)-7-methylquinoline |
| baquiloprimum [latin] |
| 1380u |
| 102280-35-3 |
| CHEMBL2105911 |
| baquiloprima |
| baquiloprime |
| 3de766vig6 , |
| baquiloprim [inn:ban] |
| baquiloprimum |
| unii-3de766vig6 |
| baquiloprim [inn] |
| baquiloprim [mart.] |
| SCHEMBL9007835 |
| baquiloprim, vetranal(tm), analytical standard |
| FT-0726966 |
| 5-((8-(dimethylamino)-7-methylquinolin-5-yl)methyl)pyrimidine-2,4-diamine |
| BCP08018 |
| DTXSID90891424 |
| 5-[[8-(dimethylamino)-7-methylquinolin-5-yl]methyl]pyrimidine-2,4-diamine |
| Q27257075 |
| baquiloprim 100 microg/ml in acetonitrile |
| 5-[[8-(dimethylamino)-7-methyl-5-quinolinyl]methyl]-2,4-pyrimidinediamine; 138ou; baquiloprim; 2,4-pyrimidinediamine, 5-[[8-(dimethylamino)-7-methyl-5-quinolinyl]methyl]- |
| CS-0015864 |
| HY-19581 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The mean elimination half-life (t1/2 beta) was 14." | ( Oral bioavailability and pharmacokinetics of baquiloprim in dwarf goats. Lewicki, J; Maas, RF; Van-Miert, AS; Witkamp, RF, 1995) | 0.55 |
| " The formulation was given by deep intramuscular injection to pigs at doses of 10 mg kg-1 and 30 mg kg-1 and the pharmacokinetic properties were investigated." | ( Pharmacokinetics of baquiloprim and sulphadimidine in pigs after intramuscular administration. Davies, AM; MacKenzie, NM, 1994) | 0.61 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In contrast to TMP (half-life about one hour), BQP was well absorbed from the gastrointestinal tract in all ages of cattle, plasma concentrations reaching a plateau on the day after dosing followed by a slow decline." | ( Baquiloprim, a new antifolate antibacterial: in vitro activity and pharmacokinetic properties in cattle. Daluge, SM; Ferone, R; Sigel, CW; White, G; Wilson, HR, 1993) | 1.73 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Nine similar calves were also infected in the same manner after dosing six hours previously with a bolus providing doses of 4 mg/kg baquiloprim and 36 mg/kg sulphadimidine." | ( Administration of a bolus formulation of baquiloprim and sulphadimidine to calves: plasma concentration--time profiles and efficacy in suppressing experimental pneumonic pasteurellosis. Dassanayake, L; White, G, 1994) | 0.76 |
| " In contrast to TMP (half-life about one hour), BQP was well absorbed from the gastrointestinal tract in all ages of cattle, plasma concentrations reaching a plateau on the day after dosing followed by a slow decline." | ( Baquiloprim, a new antifolate antibacterial: in vitro activity and pharmacokinetic properties in cattle. Daluge, SM; Ferone, R; Sigel, CW; White, G; Wilson, HR, 1993) | 1.73 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.01) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||